


## Current Treatment of Ovarian Cancer

Prof. Dr. Jalid Sehouli and Priv.-Doz. Dr. Christina Fotopoulou, Klinik für Gynäkologie, Charité - Universitätsmedizin Berlin

UNI-MED Science, 1st edition 2014, 156 pp, 60 illustrations, Hardcover, ISBN 978-3-8374-1404-2 (Germany) / ISBN 978-1-84815-212-0 (Rest of the world), Euro 29,80  
ePDF-version: ISBN 978-3-8374-5404-8, Euro 29,80



Ovarian cancer is the fifth commonest malignancy of European women, but occupies first place in the mortality statistics for gynaecological malignancies. Effective screening is not yet possible but will potentially be able to significantly improved using the micro-array technique. The postoperative residual tumour represents the most important prognostic factor, which underlines the call for centralising the treatment both of the primary cancer and for recurrence of advanced ovarian cancer. The development of new molecular biology substances has already begun and is looking for a significant improvement in treatment outcomes in relation to quality of life and survival rates. Studies have now finally shown the benefit of maintenance therapy with the anti-angiogenesis agent bevacizumab, with a significant improvement in progression-free survival.

**Klinische  
Lehrbuchreihe**



... Kompetenz und Didaktik!

**SSSSSSSSSCIENCE**